A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Public ClinicalTrials.gov record NCT07765888. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated. * This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20. Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.
Study identification
- NCT ID
- NCT07765888
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 375 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2026 (Actual)
- Primary completion
- Mar 10, 2028 (Estimated)
- Completion
- Jun 2, 2028 (Estimated)
- Last update posted
- Oct 15, 2026
2026 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cahaba Dermatology & Skin Health Center | Birmingham | Alabama | 35244 | Not yet recruiting |
| ORSO Health | Scottsdale | Arizona | 85254 | Not yet recruiting |
| Kern Research, Inc. | Bakersfield | California | 93301 | Not yet recruiting |
| Northridge Clinical Trials | Northridge | California | 91325 | Recruiting |
| University Clinical Trials, Inc | San Diego | California | 92123 | Recruiting |
| Focus Clinical Research | West Hills | California | 91307 | Not yet recruiting |
| Pediatric Skin Research | Miami | Florida | 33156 | Recruiting |
| AllerVie Clinical Research | Panama City | Florida | 32405 | Recruiting |
| GCP Research , Global Clinical Professionals | St. Petersburg | Florida | 33714 | Recruiting |
| Marietta Dermatology Clinical Research, Inc. | Marietta | Georgia | 30060 | Recruiting |
| Aeroallergy Research Laboratories of Savannah, Inc | Savannah | Georgia | 31406 | Not yet recruiting |
| Red River Research Partners LLC | Fargo | North Dakota | 58103 | Recruiting |
| Derm Texas | Dallas | Texas | 75235 | Recruiting |
| Stryde Research-Epiphany Dermatology | Southlake | Texas | 76092 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07765888, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07765888 live on ClinicalTrials.gov.